KR101643245B1 - Composition containing Gastrodia elata Blume by high pressure/enzyme dissolution decomposion for improving blood circulation - Google Patents

Abstract

The present invention relates to a composition for improving blood circulation comprising a high-pressure enzyme-decomposed Gastrodia root extract as an active ingredient. The high-pressure enzymatic hydrolyzed ginseng extract according to the present invention inhibits platelet aggregation and prolongs the bleeding time to exhibit excellent blood circulation improving effect and anti-platelet effect, and thus can be used as a medicament useful for prevention or treatment of thrombotic diseases or as a health functional food have.

Description

[0001] The present invention relates to a composition for improving blood circulation comprising a high-pressure enzyme-degrading enzyme as an active ingredient,

The present invention relates to a composition for improving blood circulation comprising Gastrodia elata Blume as an active ingredient.

Recently, circulatory diseases such as arteriosclerosis, cerebral hemorrhage, hypertension, heart disease, stroke, and cerebral infarction have been the leading causes of death in Korea as well as in developed countries. These geriatric diseases have developed into modern society, and are frequently occurring in middle and old age due to changes in dietary patterns and internal and external environmental stresses. A variety of causes can block the blood vessels and cause the diseases. If the cardiovascular system is blocked, myocardial infarction can occur. If the blood vessels in the brain are blocked, a cerebral infarction can occur. In the case of cerebral infarction, the disease may continue to progress, resulting in a stroke and death. In the United States, stroke is the third most common cause of death in adults and is known to be the most important cause of mobility. The main cause of these diseases is known as thrombus. Thrombosis is recognized as a pathological phenomenon mediated by excessive platelet aggregation. In addition, this causes a disorder of blood circulation.

Hemostasis is a mechanism to prevent hemorrhage from broken blood vessels. The hemostasis is accomplished through the activation process of platelets, the adhesion of platelets and blood vessels, and the complex interactions of blood coagulation factors that accompany them, restoring damaged blood vessels. Platelets are activated by stimulation of various agonists such as collagen, arachidonic acid, and adenosine diphosphate (ADP) during vascular injury to induce adhesion, secretion, And aggregation. These reactions are associated with haemostasis and are also known to be involved in the onset of circulatory diseases, including thrombosis.

Platelets have a distinctive discoid shape in the resting state, but when activated, they lose their original shape and undergo irregular shaped deformations with females, and the polymerization of cytoskeleton species, , Phosphorylation and the resulting interactions.

The antiplatelet agents developed so far include theopylline, molsidomin, verapamil, and nifedipine. It is known for promoting the formation of cAMP and cGMP inhibit the mobilization of Ca ^{+ 2.} Nonsteroidal compounds such as aspirin, imidazole, and indymethacin are also known to have antiplatelet activity by inhibiting the production of thromboxane A2. However, the drugs made of the above-mentioned chemicals have various problems such as excessive hemostasis, infertility and digestive disorders in the human body. Accordingly, in order to search for a substance showing the same effect while reducing side effects of drugs made of the above-mentioned chemical substances, many researches on substances that improve blood circulation from natural substances have been conducted.

In the food industry, high-pressure processing technology has been used primarily for the sterilization of harmful microorganisms in foods. However, recently, high-pressure technology has become advantageous as a non-heating technology capable of providing water-soluble and extractive effects while maintaining the color, flavor, and nutrients of useful ingredients from animal and plant materials, The high-pressure treatment device that can be used has been developed, and the utilization rate has been gradually increasing, centering on manufacturers of small-sized food materials and beauty materials.

The high-pressure treatment process accelerates the reaction of the food process as the volume decreases as the pressure increases. When the enzyme is subjected to high pressure treatment, the structure of the three-dimensional macromolecule of the molecule is changed by affecting hydrogen bonding by high pressure, It maintains the natural flavor and taste, and at the same time inhibits the enzyme activity and improves the preservability. The degree of inactivation of the enzyme depends on the kind of enzyme, pH, temperature, time, and the quality factor such as phenolases, pectinases and peroxidases contained in the food. It is important.

Meanwhile, Pegasus (天麻, Gastrodia Rhizoma) is not a leaf chlorophyll as referring to the root of the number of perennial plant belonging to the orchid neck Orchidaceae (Orchidaceae) native to Japan, Korea, China and other self-harm fucked (Pegasus, Gastrodia elata Blume) Is a medicinal crop with the characteristics that it grows by receiving nutrition from the parasitic fungus. The stem is like a potato and the grain is arranged on the surface. The stem is a column of yellowish red color and the height is about 1m. It is a yellow-flowering plant in menstruation. It is also called the other names such as red roots, 鬼 之 宇, 麻 母, 神 草, and 风风 草. The major constituents of chima are gastrodine, p- hydroxybenzaldehyde (HBAD), p- hydroxybenzyl alcohol (HBA), vanillyl alcohol (VA), vanillin, parishins B, C, 4,4-dihydroxybenzyl sulfoxide and gastrol. Ginseng is a medicinal herb that is classified as medicinal herb and has a weakness as a medicinal herb. Clinical efficacy of Chunma is found in various herbal medicines such as herbaceous gangbuk and Dongbibogam. It is known to be effective for diseases such as hypertension, headache, paralysis, neurological diseases, diabetes, and stress and fatigue.

As described above, various pharmacological effects of Chima are known, but it has not yet been clarified whether or not the high-pressure enzymatic hydrolyzate has a blood circulation improving effect. Therefore, the inventors of the present invention have conducted research using a high-pressure enzyme-degrading enzyme to develop a new drug having a blood circulation-improving effect. As a result, the present inventors have completed the present invention by confirming that the extract of high-

It is an object of the present invention to provide a composition for improving blood circulation comprising a high-pressure enzyme-decomposed Gastrodia crassa extract as an active ingredient.

It is also an object of the present invention to provide a composition for the prevention or treatment of thrombotic diseases, which comprises a high-pressure enzyme-decomposed Gammachrome extract as an active ingredient.

 In order to accomplish the above object, the present invention provides a composition for improving circulation comprising the high-pressure enzyme-decomposed Chimpanzee extract as an active ingredient.

The present invention also provides a composition for the prevention or treatment of thrombotic diseases, which comprises a high-pressure enzyme-decomposed Gammachrome extract as an active ingredient.

Since the high-pressure enzyme-decomposed Gastrodia elata extract according to the present invention inhibits platelet aggregation and prolongs the bleeding time to exhibit excellent blood circulation improving effect and anti-platelet effect, it can be used as a medicament useful for prevention or treatment of thrombotic diseases or as a health functional food have.

FIG. 1 is a graph showing the results of measuring the inhibitory effect on platelet aggregation after treating the blood of a rat with a high-pressure enzyme-decomposed Ganoderma lucidum extract.
FIG. 2 is a graph showing the results of measurement of the inhibitory effect on platelet aggregation in rats fed with high-pressure enzyme-degraded chymase extract.

The present invention provides a composition for improving circulation comprising an extract of Gastrodia elata Blume as an active ingredient.

The composition comprises a pharmaceutical composition or a food composition.

Hereinafter, the present invention will be described in detail.

In the composition of the present invention, the high-pressure enzymatic hydrolyzed ginseng extract, which is an active ingredient, is extracted after high-pressure treatment at a pressure of 20 to 100 bar after addition of the enzyme, and the enzyme is preferably termamyl, celluclast, But is not limited to, viscozyme.

At this time, the termaryl, cellulose and viscose may be mixed in a ratio of preferably 0.8 to 1.2: 0.8 to 1.2: 0.8 to 1.2 parts by weight, and the enzyme may be mixed with 4 to 8 parts by weight And preferably 6 parts by weight can be added.

The high pressure treatment may preferably be carried out at a temperature of 40 to 60 DEG C for 20 to 30 hours, more preferably at a temperature of 50 DEG C for 24 hours. The chewy gum extract of the present invention, which has been subjected to enzyme addition and high pressure treatment, can produce high quality extracts as compared with the conventional heat treatment process, and can improve productivity and efficiency.

The chimpanzee extract of the present invention can be obtained by extracting the residue from the enzyme and the high-pressure treatment using one or more solvents selected from water, alcohols having 1 to 4 carbon atoms, or a mixed solvent thereof. The alcohol having 1 to 4 carbon atoms is methanol or ethanol, preferably ethanol. Extraction can be performed by a hot water extraction or a reflux cooling extraction method.

The present inventors have confirmed that the extract of Chimmae inhibits platelet aggregation and prolongs the bleeding time to exhibit excellent blood circulation improving effect and anti-platelet effect. The present invention provides a composition for preventing or treating thrombotic diseases containing the above-described high-pressure enzyme-degraded Gastrodia crurus extract as an active ingredient.

The composition comprises a pharmaceutical composition or a food composition.

The thrombotic disease includes, but is not limited to, arterial thrombosis, venous thrombosis, pulmonary embolism, chronic venous ischemia, varicose veins, deep vein thrombosis, arteriosclerosis, cerebral hemorrhage, stroke or cerebral infarction.

The composition of the present invention may further contain at least one known effective ingredient having blood circulation improving effect together with the above-mentioned chymus extract.

The compositions of the present invention may further comprise suitable carriers, excipients and diluents conventionally used in the manufacture of pharmaceutical compositions. In addition, it can be formulated in the form of powders, granules, tablets, capsules, suspensions, emulsions, oral preparations such as syrups and aerosols, external preparations, suppositories and sterilized injection solutions according to a conventional method. Suitable formulations known in the art are preferably those as disclosed in Remington ' s Pharmaceutical Science, recently, Mack Publishing Company, Easton PA. Examples of carriers, excipients and diluents which may be included include lactose, dextrose, sucrose, sorbitol, mannitol, xylitol, erythritol, maltitol, starch, acacia rubber, alginate, gelatin, calcium phosphate, calcium silicate, cellulose, methylcellulose, Cellulose, polyvinylpyrrolidone, water, methylhydroxybenzoate, propylhydroxybenzoate, talc, magnesium stearate, and mineral oil. When the composition is formulated, it is prepared using a diluent such as a filler, an extender, a binder, a wetting agent, a disintegrant, a surfactant, or an excipient usually used. Solid formulations for oral administration include tablets, pills, powders, granules, capsules and the like, which may contain at least one excipient such as starch, calcium carbonate, sucrose, lactose, Gelatin and the like. In addition to simple excipients, lubricants such as magnesium stearate and talc are also used. Examples of the liquid preparation for oral use include suspensions, solutions, emulsions, and syrups. In addition to water and liquid paraffin, simple diluents commonly used, various excipients such as wetting agents, sweeteners, fragrances, preservatives and the like may be included . Formulations for parenteral administration include sterilized aqueous solutions, non-aqueous solutions, suspensions, emulsions, freeze-dried preparations, and suppositories. Examples of the suspending agent include propylene glycol, polyethylene glycol, vegetable oil such as olive oil, injectable ester such as ethyl oleate, and the like. Examples of the suppository base include witepsol, macrogol, tween 61, cacao butter, laurin, glycerogelatin and the like.

The term "administering" as used herein is meant to provide any desired composition of the invention to a subject in any suitable manner.

The preferred dosage of the pharmaceutical composition of the present invention varies depending on the condition and the weight of the individual, the degree of disease, the type of drug, the route of administration and the period of time, but can be appropriately selected by those skilled in the art. For the desired effect, the daily dose of the high-pressure enzymatic degrading enzyme of the present invention may be administered in an amount of 1 mg / kg to 10000 mg / kg, and may be administered once a day or several times.

The pharmaceutical composition of the present invention may be administered to a subject in various routes. All modes of administration may be expected, for example, by oral, rectal or intravenous, intramuscular, subcutaneous, intra-uterine dural or intracerebral injection.

The composition of the present invention can be used alone or in combination with methods using surgery, radiation therapy, hormone therapy, chemotherapy and biological response modifiers for the improvement of blood circulation or prevention or treatment of thrombotic diseases.

The composition of the present invention may be added to health functional foods for the purpose of improving blood circulation or preventing or improving thrombotic diseases. When the high-pressure enzyme-decomposed Chimpanzee extract of the present invention is used as a food additive, the high-pressure enzyme decomposition enzyme can be used as it is, or it can be used together with other food or food ingredients, and can be suitably used according to a conventional method. The amount of the active ingredient to be mixed can be suitably determined according to the intended use (prevention, health or therapeutic treatment). Generally, in the production of a food or beverage, the high-pressure enzymatically decomposed starch of the present invention is added in an amount of not more than 15% by weight, preferably not more than 10% by weight based on the raw material. However, in the case of long-term intake for the purpose of health and hygiene or for the purpose of controlling health, the amount may be less than the above range, and since there is no problem in terms of safety, the active ingredient may be used in an amount exceeding the above range.

There is no particular limitation on the kind of the food. Examples of foods to which the above substances can be added include dairy products including meat, sausage, bread, chocolate, candy, snacks, confectionery, pizza, ramen and other noodles, gums, ice cream, various soups, drinks, tea, Alcoholic beverages, and vitamin complexes, all of which include health foods in a conventional sense.

The health beverage composition of the present invention may contain various flavors or natural carbohydrates as an additional ingredient such as ordinary beverages. The natural carbohydrates may be monosaccharides such as glucose and fructose, disaccharides such as maltose and sucrose, natural sweeteners such as dextrin and cyclodextrin, synthetic sweeteners such as saccharine and aspartame, and the like. The ratio of the natural carbohydrate is generally about 0.01 to 10 g, preferably about 0.01 to 0.1 g per 100 ml of the composition of the present invention.

In addition to the above, the composition of the present invention may further contain various nutrients, vitamins, electrolytes, flavors, colorants, pectic acid and salts thereof, alginic acid and salts thereof, organic acids, protective colloid thickeners, pH adjusters, stabilizers, preservatives, glycerin, A carbonating agent used in a carbonated beverage, and the like. In addition, the composition of the present invention may comprise flesh for the production of natural fruit juices, fruit juice drinks and vegetable drinks. These components may be used independently or in combination. Although the ratio of such additives is not critical, it is generally selected in the range of 0.01 to 0.1 parts by weight per 100 parts by weight of the composition of the present invention.

Hereinafter, preferred embodiments and experimental examples are presented to facilitate understanding of the present invention. However, the following examples and experimental examples are provided only for the purpose of easier understanding of the present invention, and the present invention is not limited by the examples, experimental examples and production examples.

Example 1. Preparation of high-pressure enzyme digesting chewing gum

400 mg of Chunma powder and 1.6 L of distilled water were mixed, and then 8 mL of each of Terumamil 120 L, Celluclast 1.5 L and Viscotextile 1% corresponding to 2% (w / v) of the substrate was added to the polyethylene film wrapping paper, And then subjected to high pressure treatment at 100 MPa and 50 < 0 > C for 24 hours. After completion of the reaction, the reaction mixture was divided into two groups, enzyme-inactivation (100 ° C., 10 min.) And enzyme-activation. The reaction mixture was centrifuged (7000 rpm, 10 min, 20 ° C.) paper No. 4) to obtain 810 mL of the high-pressure / enzyme decomposition of the enzyme inactive group and 810 mL of the high-pressure enzyme decomposition residue of the enzyme active group, and then the hydrolyzate and the residue were obtained. The extracts and residues extracted from the high pressure enzyme digestion comparison group at 50 ℃ for 24 hours were obtained.

Example 2: Preparation of Ganoderma lucidum extract

10 g of the residue of the residue of the high-pressure enzyme-degraded chymase prepared in Example 1 was repeatedly extracted twice with low-temperature ethanol through a reflux extracting apparatus to obtain 5 g (50% yield) of a sample.

EXPERIMENTAL EXAMPLE 1. Analysis of the content of the indicator component of the high-pressure enzyme-degrading Ganoderma lucidum extract

The content of the indicator components of the high-pressure enzymatically hydrolyzed chymus extract prepared in Example 2 was confirmed by HPLC (High-performance liquid chromatography). The column temperature was set at 30 ° C using a Waters SunFire ^™ C18 (Waters Corp., Milford, USA), and the mobile phase was measured at 280 nm using a detector of H ₃ PO ₄ and acetonitrile. Table 1 shows the results.

Surface component Content (mg / g) Gum extract High-Pressure Enzymatic Hydrolyzed Ginger Extract Gastrodin 29.88 2.82 p -hydroxybenzyl alcohol (HBA) 2.64 37.88 Vanillyl alcohol < RTI ID = 0.0 > 54.49 5.66 p -Hydroxybenzylaldehyde (HBAD) 0.24 0.4 Vanillin 0.42 0.66

As shown in Table 1, analysis of the five indicators matter content after the high pressure decomposition enzyme before each Gasthof Rodin (Gastrodin) 29.88 mg / g and 2.82 mg / g, p - hydroxybenzyl alcohol (HBA; p -hydroxybenzyl alcohol) 2.64 mg / g and 37.88 mg / g, vanillyl alcohol (vanillyl alcohol) 54.49 mg / g and 5.66 mg / g, p- hydroxybenzyl aldehyde (HBAD; p- Hydroxybenzaldehyde) 0.24 mg / g and 0.4 mg / g and vanillin was found to be 0.42 mg / g and 0.66 mg / g, respectively. The results showed that the content of p - hydroxybenzyl alcohol, vanillyl alcohol, p - hydroxybenzylaldehyde and vanillin was higher in the high -

Experimental Example 2: Confirmation of platelet aggregation inhibitory effect of high-pressure enzymatic hydrolyzate extract

Platelet aggregation experiments were performed to confirm the inhibitory effect of platelet aggregation inhibition of high - First, Sprague-Dawley (SD) rats were anesthetized with diethyl ether to obtain platelets. Blood was collected from the abdominal artery using sodium citrate (3.8%, 1: 9 v / v). The collected blood was centrifuged at 140 xg for 10 minutes to obtain platelet rich plasma (PRP), followed by centrifugation at 800 x g to obtain platelet-poor plasma (PPP) . PRP was fixed at 4 x 10 ⁸ platelets / ml. Chromosomes and high-pressure enzymatic hydrolysates were treated with 0.5, 1, and 2 mg / ml of fixed PRP, respectively, and incubated at 37 ° C for 10 minutes. Then, platelet aggregation was induced with collagen, and an aggregator (Chrono-Log 700- 2, USA). The results are shown in FIG.

As shown in FIG. 1, when platelet aggregation was induced by collagen, the inhibition of platelet aggregation was statistically significantly inhibited in the case of chimma and high-pressure enzymatic degradation in comparison with the control group. In particular, the effect of inhibiting platelet aggregation of high- .

Experimental Example 3. Confirmation of aPTT and PT of high-pressure enzymatic hydrolyzate extract

Plasma coagulation time was measured by a coagulometer (Coatron M4, Germany) via the endogenous pathway aPTT and the exogenous pathway PT in order to determine the effect of the high-pressure enzymatic hydrolyzate extract on blood coagulation factors. First, human plasma was treated with 0.5, 1, and 2 mg / ml of high-pressure enzyme digestion chymase, respectively, followed by incubation at 37 ° C for 1 minute. aPTT was measured by adding 100 μl of aPTT measuring reagent and 100 μl of 20 mM CaCl _{2 to} 100 μl of a sample, and measuring the exogenous pathway after adding 200 μl of PT measuring reagent to 100 μl of the sample, and the results are shown in Table 2 Respectively.

sample Concentration (mg / ml) aPTT (sec) PT (sec) Control group 47.87 ± 0.91 16.13 + 0.06 Chunma 0.5 49.33 + - 0.58 17.67 ± 0.90 One 49.97 + - 0.12 16.60 + - 0.44 2 50.03 + - 0.12 16.07 ± 0.12 High pressure enzyme digestion 0.5 50.07 ± 0.12 16.33 + - 0.42 One 49.60 ± 0.36 16.63 + - 0.38 2 49.95 + 0.07 16.33 + - 0.42

As shown in Table 2, it was confirmed that the high-pressure enzymatically degraded chymase did not change the coagulation time.

Experimental Example 3. Animal Experiment Using High-Pressure Enzymatic Hydrolysis of Chimpanzee Extract

3-1. Inhibition of platelet aggregation by high-pressure enzymatic hydrolysis of Ganoderma lucidum extract

Platelet aggregation was induced to inhibit platelet aggregation of high - First, the rats were orally administered to the rats at a dose of 20, 100, or 500 mg / kg / day for a week, and then fasted on the day of the experiment. After PRP isolated from the blood of rats was incubated, platelet aggregation was induced with collagen and measured with an aggregometer (Chrono-Log 700-2, USA). The results are shown in Fig.

As shown in FIG. 2, it was confirmed that both the chimma and the high-pressure enzymatic degradation chimney inhibited the platelet aggregation statistically, as compared with the control group, and the platelet aggregation inhibition effect of the high-pressure enzymatic hydrolyzed chimma extract was better than the chimma extract.

3-2. APTT and PT

To investigate the effects of high-pressure enzymatic hydrolyzate extracts on blood coagulation factors, 20, 100 or 500 mg / kg / day of high-pressure enzymatic hydrolyzate extract was orally administered to rats for one week. After incubation, 100 μl of aPTT assay reagent and 100 μl of 20 mM CaCl ₂ were added to 100 μl of PPP, and 200 μl of PT assay reagent was added to 100 μl of PPP And the results are shown in Table 3. < tb >< TABLE >

Group Dose (mg / kg) aPTT (sec) PT (sec) Normal 17.51 + - 0.71 25.11 + 1.50 Chunma 20 17.37 ± 1.77 25.75 ± 0.77 100 17.20 + 0.08 25.25 + 1.21 500 17.06 + - 0.54 25.31 + - 0.90 High pressure enzyme digestion 20 17.26 ± 0.54 25.16 ± 1.47 100 17.44 ± 1.09 23.83 + - 0.76 500 18.03 + - 0.78 25.98 + 2.01 aspirin 20 17.41 + - 1.65 25.75 ± 0.77

As shown in Table 3, it was confirmed that the high-pressure enzymatic hydrolyzate extract of aPTT and PT did not change plasma coagulation time.

3-3. Bleeding time in the treatment of high-pressure enzymatic hydrolysis of Ganoderma lucidum extract

To investigate the abnormalities of platelets and plasma factors, we examined the effects of high - pressure enzymatic hydrolysis of Chimmae extract on bleeding time. Bleeding time was measured by the Hornstra method. Ketamine and rumpun were mixed and injected into the abdominal cavity. After the anesthetization, 3 mm of the rat tail was cut and the time was measured until the hemostasis was carried out in 0.9% physiological saline maintained at 37 ° C. The results are shown in Table 4.

Group Dose (mg / kg) Bleeding time (sec) Normal 500.67 ± 68.39 Chunma
20 619.67 + - 63.81 100 773.33 + - 82.40 * 500 915.33 + - 68.54 ** High pressure enzyme digestion
20 689.00 ± 87.28 * 100 891.33 + - 125.56 * 500 1274.67 ± 137.47 ** aspirin 20 1800.00 ± 0.00 ***

As shown in Table 4, it was confirmed that the bleeding time was significantly longer than that of the control group when the high-pressure enzymatic hydrolyzate extract was treated.

Hereinafter, formulation examples of the pharmaceutical composition and the food composition of the present invention will be described, but the present invention is not intended to be limited thereto but is specifically described.

Formulation Example 1. Pharmaceutical preparation

1-1. Manufacture of Powder

High-pressure enzyme decomposition 20mg

Lactose 100 mg

Talc 10 mg

The above components are mixed and filled in airtight bags to prepare powders.

1-2. Manufacture of tablets

High pressure enzyme decomposition 10 mg

Corn starch 100 mg

Lactose 100 mg

Magnesium stearate 2 mg

After mixing the above components, tablets are prepared by tableting according to the usual preparation method of tablets.

1-3. Preparation of capsules

High pressure enzyme decomposition 10 mg

Crystalline cellulose 3 mg

Lactose 14.8 mg

Magnesium stearate 0.2 mg

The above components are mixed according to a conventional capsule preparation method and filled in gelatin capsules to prepare capsules.

1-4. Injection preparation

High pressure enzyme decomposition 10 mg

180 mg mannitol

Sterile sterilized water for injection 2974 mg

Na ₂ HPO ₄ .2H ₂ O 26 mg

(2 ml) per 1 ampoule in accordance with the usual injection preparation method.

1-5. Manufacture of liquid agent

High pressure enzyme decomposition Chunma 20 mg

10 g per isomer

5 g mannitol

Purified water quantity

Each component was added and dissolved in purified water according to the usual liquid preparation method, and the lemon flavor was added in an appropriate amount. Then, the above components were mixed, and purified water was added thereto. The whole was added with purified water to adjust the total volume to 100 ml, And sterilized to prepare a liquid preparation.

Formulation Example 2. Food preparation

2-1. Manufacture of health food

High pressure enzyme decomposition 100 mg

Vitamin mixture quantity

Vitamin A acetate 70 μg

Vitamin E 1.0 mg

Vitamin B1 0.13 mg

0.15 mg of vitamin B2

Vitamin B6 0.5 mg

Vitamin B12 0.2 μg

Vitamin C 10 mg

Biotin 10 μg

Nicotinic acid amide 1.7 mg

Folic acid 50 μg

Calcium pantothenate 0.5 mg

Mineral mixture quantity

1.75 mg of ferrous sulfate

0.82 mg of zinc oxide

Magnesium carbonate 25.3 mg

Potassium monophosphate 15 mg

Secondary calcium phosphate 55 mg

Potassium citrate 90 mg

Calcium carbonate 100 mg

Magnesium chloride 24.8 mg

Although the composition ratio of the above-mentioned vitamin and mineral mixture is comparatively mixed with a composition suitable for health food as a preferred embodiment, the compounding ratio may be arbitrarily modified, and the above ingredients are mixed according to a conventional method for producing healthy foods , Granules can be prepared and used in the manufacture of health food compositions according to conventional methods.

2-2. Manufacture of health drinks

High pressure enzyme decomposition 100 mg

Vitamin C 15 g

Vitamin E (powder) 100 g

19.75 g of ferrous lactate

3.5 g of zinc oxide

Nicotinic acid amide 3.5 g

Vitamin A 0.2 g

Vitamin B1 0.25 g

Vitamin B2 0.3 g

Water quantity

The above components were mixed according to a conventional health drink manufacturing method, and the mixture was stirred and heated at 85 DEG C for about 1 hour. The solution thus prepared was filtered and sterilized in a sterilized 2 liter container, It is used in the production of the health beverage composition of the invention.

Although the compositional ratio is relatively mixed with a component suitable for a favorite drink, it is also possible to arbitrarily modify the compounding ratio according to the regional or national preference such as the demand class, the demanding country, and the use purpose.

Claims (9)

(Gastrodia elata Blume) extract obtained by high-pressure treatment at 20 to 100 bar pressure with addition of enzymes mixed at a ratio of 0.8-1.2: 0.8-1.2: 0.8-1.2 parts by weight of termarum, celluclast and viscose, A pharmaceutical composition for improving circulation comprising as an active ingredient. delete delete The pharmaceutical composition for improving circulation according to claim 1, wherein the high-pressure treatment is performed at a temperature of 40 to 60 DEG C for 20 to 30 hours. The pharmaceutical composition for improving circulation according to claim 1, wherein the chymus extract is extracted with a solvent selected from water, an alcohol having 1 to 4 carbon atoms, or a mixed solution thereof. The present invention relates to a method for producing an extract of Chimpanzee, comprising the step of adding an enzyme prepared by mixing termarum, cellulose and viscose at a ratio of 0.8-1.2: 0.8-1.2: 0.8-1.2 parts by weight, and treating the mixture with high pressure at a pressure of 20-100 bar, A food composition for improving blood circulation. The present invention relates to a method for producing an extract of Chimpanzee, comprising the step of adding an enzyme prepared by mixing termarum, cellulose and viscose at a ratio of 0.8-1.2: 0.8-1.2: 0.8-1.2 parts by weight, and treating the mixture with high pressure at a pressure of 20-100 bar, A pharmaceutical composition for the prevention or treatment of thrombotic diseases. The method according to claim 7, wherein the thrombotic disease is selected from the group consisting of arterial thrombosis, venous thrombosis, pulmonary embolism, chronic venous ischemia, varicose veins, deep vein thrombosis, arteriosclerosis, cerebral hemorrhage, stroke and cerebral infarction. A pharmaceutical composition for preventing or treating a disease. The present invention relates to a method for producing an extract of Chimpanzee, comprising the step of adding an enzyme prepared by mixing termarum, cellulose and viscose at a ratio of 0.8-1.2: 0.8-1.2: 0.8-1.2 parts by weight, and treating the mixture with high pressure at a pressure of 20-100 bar, A food composition for improving blood clotting.

Images